Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, March 19, 2014 LONDON, March 19, 2014 /PRNewswire/ -- On Tuesday, March 18, 2014, the NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones Industrial Average closed the session at 16,336.19, up 0.55% and the S&P 500 ended the day at 1,872.25, higher by 0.72%. The gains were broad based with 9 of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index closed the day at 688.96, up 1.17%, and the same has gained 1.57% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK) and Eli Lilly & Co. (NYSE: LLY). Free technical research on BMY, JNJ, MRK and LLY can be downloaded upon signing up at: http://www.investor-edge.com/339-register On Tuesday, shares in Bristol-Myers Squibb Co. edged 0.02% higher, finishing the session at $54.73. The stock recorded a trading volume of 5.29 million shares as compared to a three months average volume of 8.64 million shares. The stock fluctuated between $54.28 and $54.93 during the session. Shares of the company traded at a PE ratio of 32.63. Bristol-Myers Squibb Co.'s shares have gained 1.02% in the previous three trading sessions, 0.18% in the last one month and 2.97% on YTD basis. The company's shares are trading above its 50-day and 200-day moving averages. Bristol-Myers Squibb Co.'s 50-day moving average of $53.35 is above the 200-day moving average of $48.82. Moreover, the stock is trading at the Relative Strength Index (RSI) of 53.29. Sign up today to read free research on BMY at: http://www.investor-edge.com/339-BMY-19Mar2014.pdf Shares in Johnson & Johnson recorded a trading of 5.86 million shares, as compared with a three months average volume of 8.10 million shares. The stock ended the day at $93.94, up 0.01% and at an intraday range of $93.48 and $94.24. Shares of the company traded at a PE ratio of 17.15. Johnson & Johnson's shares have advanced 1.01% in the previous three trading sessions, 1.92% in the last one month and 2.57% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages. Johnson & Johnson's 50-day moving average of $92.08 is above the 200-day moving average of $90.58. Furthermore, the stock is trading at the Relative Strength Index (RSI) of 60.42. Sign up today to read free research on JNJ at: http://www.investor-edge.com/339-JNJ-19Mar2014.pdf On Tuesday, shares in Merck & Co Inc. closed the day at $56.36, up 0.18%. A total of 7.04 million shares were traded, which is below the three months average volume of 12.32 million. The company's shares oscillated between $56.16 and $56.56 during the trading session. Merck & Co Inc.'s shares have gained 1.02% in the previous three trading session, 1.20% in the last one month, and 12.61% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages. Merck & Co Inc.'s 50-day moving average of $54.09 is above the 200-day moving average of $49.41. Furthermore, the stock is trading at the Relative Strength Index (RSI) of 55.01. Sign up today to read free research on MRK at: http://www.investor-edge.com/339-MRK-19Mar2014.pdf Eli Lilly & Co.'s stock recorded a trading volume of 4.06 million shares, as compared with a three months average volume of 5.50 million shares. The stock finished the day at $59.40, up 0.90% after trading between $58.81 and $59.70. Shares of the company traded at a PE ratio of 13.44. Eli Lilly & Co. shares have advanced 1.82% in the previous three trading sessions, 7.51% in the last one month and 16.47% on YTD basis. The company's shares are trading above its 50-day and 200-day moving averages. Eli Lilly & Co.'s 50-day moving average of $55.45 is above the 200-day moving average of $52.28. Additionally, shares of the company are trading at the Relative Strength Index (RSI) of 60.29. Sign up today to read free research on LLY at: http://www.investor-edge.com/339-LLY-19Mar2014.pdf =============== EDITOR'S NOTES: =============== 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com. 5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com. 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Investor-Edge Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
China Cuts Benchmark Interest Rates to Boost Economy
Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
Press spacebar to pause and continue. Press esc to stop.